Intraduodenal levodopa-carbidopa intestinal gel infusion improves both motor performance and quality of life in advanced Parkinson’s disease
- 1 March 2016
- journal article
- clinical trial
- Published by Elsevier in Journal of Clinical Neuroscience
- Vol. 25, 41-45
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label resultsMovement Disorders, 2014
- Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsParkinsonism & Related Disorders, 2013
- Systematic review of levodopa dose equivalency reporting in Parkinson's diseaseMovement Disorders, 2010
- Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's diseaseActa Neurologica Scandinavica, 2009
- The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 yearsMovement Disorders, 2008
- Duodenal levodopa infusion for advanced Parkinson's disease: 12‐month treatment outcomeMovement Disorders, 2007
- Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson diseaseNeurology, 2005
- Duodenal levodopa infusion in Parkinson's disease - long-term experienceActa Neurologica Scandinavica, 2001
- Erratic gastric emptying of levodopa may cause “random” fluctuations of parkinsonian mobilityNeurology, 1988
- The “On–Off” Phenomenon in Parkinson’s DiseaseNew England Journal of Medicine, 1984